

5.85.26

| | | | |
|--------------------|----------------------|------------------------------|---------------|
| Section: | Prescription Drugs | Effective Date: | July 1, 2022 |
| Subsection: | Hematological Agents | Original Policy Date: | July 14, 2017 |
| Subject: | Haegarda | Page: | 1 of 5 |

Last Review Date: June 16, 2022

Haegarda

Description

Haegarda (C1 esterase inhibitor [human])

Background

Haegarda is a C1-esterase inhibitor used for the routine prophylaxis against angioedema attacks in patients with hereditary angioedema (HAE). HAE is caused by having insufficient amounts of a plasma protein called C1-esterase inhibitor. People with HAE can develop rapid swelling of the hands, feet, limbs, face, intestinal tract, or airway. These acute attacks of swelling can occur spontaneously, or can be triggered by stress, surgery, or infection. Swelling of the airway is potentially fatal without immediate treatment. Haegarda is intended to restore the level of functional C1-esterase inhibitor in a patient's plasma, thereby preventing the acute attack of swelling (1-4).

Regulatory Status

FDA-approved indication: Haegarda is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) (C1-INH) indicated for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients 6 years of age and older (2).

Hypersensitivity reactions may occur. Epinephrine should be immediately available to treat any acute severe hypersensitivity reactions following discontinuation of administration (2).

Thrombotic events may occur with Haegarda treatment. Monitor closely patients with known risk factors for thrombotic events (2).

Related policies

| | | | |
|--------------------|----------------------|------------------------------|---------------|
| Section: | Prescription Drugs | Effective Date: | July 1, 2022 |
| Subsection: | Hematological Agents | Original Policy Date: | July 14, 2017 |
| Subject: | Haegarda | Page: | 2 of 5 |

Berinert, Cinryze, Icatibant, Kalbitor, Orladeyo, Ruconest, Takhzyro

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Haegarda may be considered **medically necessary** in patients 6 years of age or older for the routine prevention of hereditary angioedema (HAE) attacks and if the conditions indicated below are met.

Haegarda may be considered **investigational** in patients less than 6 years of age and for all other indications.

Prior-Approval Requirements

Age 6 years of age or older

Diagnosis

Patient must have the following:

1. Hereditary Angioedema (HAE) with **ONE** of the following:
 - a. Patient has a C1 inhibitor deficiency or dysfunction as confirmed by laboratory testing **AND ALL** of the following:
 - i. C4 level below the lower limit of normal as defined by the laboratory performing the test
 - ii. C1 inhibitor (C1-INH) antigenic level below the lower limit of normal as defined by the laboratory performing the test **OR** normal C1-INH antigenic level and a low C1-INH functional level (functional C1-INH less than 50% or C1-INH functional level below the lower limit of normal as defined by the laboratory performing the test)
 - b. Patient has normal C1 inhibitor as confirmed by laboratory testing **AND ONE** of the following:
 - i. F12, angiopoietin-1, plasminogen, or kininogen-1 (KNG1) gene mutation as confirmed by genetic testing
 - ii. Documented family history of angioedema and the angioedema was refractory to a trial of high-dose antihistamine (e.g.,

| | | | |
|--------------------|----------------------|------------------------------|---------------|
| Section: | Prescription Drugs | Effective Date: | July 1, 2022 |
| Subsection: | Hematological Agents | Original Policy Date: | July 14, 2017 |
| Subject: | Haegarda | Page: | 3 of 5 |

cetirizine) for at least one month

AND ALL of the following:

1. Used for the routine prevention of hereditary angioedema attacks
2. **NO** dual therapy with other agents for the prevention of hereditary angioedema attacks (e.g., Cinryze, Orladeyo, Takhzyro)
3. Inadequate treatment response or intolerance to a short-term course (5-days or less) of an androgen such as danazol, or a contraindication to one such as:
 - a. Undiagnosed abnormal genital bleeding
 - b. Markedly impaired hepatic, renal, or cardiac function
 - c. Pregnancy (member is currently pregnant or may become pregnant)
 - d. Breast feeding
 - e. Porphyria
 - f. Androgen-dependent tumor
 - g. Active thrombosis or history of thromboembolic disease
 - h. Prepubertal child

Prior – Approval *Renewal* Requirements

Age 6 years of age and older

Diagnosis

Patient must have **ALL** of the following:

1. Hereditary Angioedema (HAE)
 - a. Routine prevention of hereditary angioedema attacks
 - b. Patient has experienced a significant reduction in frequency of hereditary angioedema attacks since starting treatment
 - c. **NO** dual therapy with other agents for the prevention of hereditary angioedema attacks (e.g., Cinryze, Orladeyo, Takhzyro)

[Policy Guidelines](#)

Pre - PA Allowance

None

| | | | |
|--------------------|----------------------|------------------------------|---------------|
| Section: | Prescription Drugs | Effective Date: | July 1, 2022 |
| Subsection: | Hematological Agents | Original Policy Date: | July 14, 2017 |
| Subject: | Haegarda | Page: | 4 of 5 |

Prior - Approval Limits

Duration 12 months

Prior – Approval *Renewal* Limits

Same as above

Rationale

Summary

Haegarda is a C1-esterase inhibitor indicated for routine prophylaxis against angioedema attacks in patients 6 years of age and older with Hereditary Angioedema (HAE). HAE symptoms include episodes of edema (swelling) in various body parts including the hands, feet, face, and airway. HAE is caused by mutations to C1-esterase-inhibitor (C1-INH). The safety and efficacy of Haegarda in children less than 6 years of age has not been established. Persons who experience frequent and/or severe episodes may be candidates for prophylactic treatment (1-4).

Prior authorization is required to ensure the safe, clinically appropriate and cost-effective use of Haegarda while maintaining optimal therapeutic outcomes.

References

1. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med. Sep 4 2008;359(10):1027-36.2.
2. Haegarda. [package insert]. Kankakee, IL; CSL Behring LLC; January 2022.
3. Zuraw BL, Banerji A, Bernstein JA, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol: In Practice. 2013; 1(5): 458-467.
4. Wintenberger C, Boccon-Gibod I, Launay D, et al. Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients. Clin Exp Immunol 2014; 178:112.

Policy History

| Date | Action |
|----------------|----------------|
| July 2017 | Addition to PA |
| September 2017 | Annual review |

5.85.26

| | | | |
|--------------------|----------------------|------------------------------|---------------|
| Section: | Prescription Drugs | Effective Date: | July 1, 2022 |
| Subsection: | Hematological Agents | Original Policy Date: | July 14, 2017 |
| Subject: | Haegarda | Page: | 5 of 5 |

| | |
|----------------|--|
| December 2017 | Annual editorial review and reference update Addition of inadequate treatment response, intolerance, or contraindication to a danazol or tranexamic acid per SME |
| March 2018 | Annual review |
| September 2018 | Changed wording of no dual therapy requirement |
| November 2018 | Annual editorial review and reference update. Removal of requirement to try and fail tranexamic acid and reworded danazol or androgen trial requirement per SME |
| September 2019 | Annual review |
| September 2020 | Annual review and reference update |
| December 2020 | Age requirement reduced from 12 and older to 6 and older |
| March 2021 | Annual editorial review |
| April 2021 | Added initiation requirements including C1 inhibitor testing, C4 testing, C1-INH testing, gene mutation testing, or documented family history of refractory angioedema and continuation requirement for significant reduction in frequency of HAE attacks since starting therapy per FEP |
| June 2021 | Annual review |
| June 2022 | Annual review and reference update |

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on June 16, 2022 and is effective on July 1, 2022.